What is CYTK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 8.75B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CYTK?

P/E (TTM) is n/a and 52-week range is $54.30 to $88.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CYTK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CYTK?

The company profile lists revenue (TTM) near $69M, net income (TTM) near $-91.76B, EPS (TTM) near $-7.22 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Cytokinetics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in South San Francisco, California, US, 135.6M shares outstanding, ISIN US23282W6057 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Cytokinetics Inc

$CYTK

Health Care · Biotechnology

IR Run Scenarios

$62.91

+1.45%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 673 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Employees

673

Website

cytokinetics.com/

IPO

2004-04-29

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)